Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00439374 · ClinicalTrials.gov registry record · Phase 3

RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix

A Phase 3 study, sponsored by The George Washington University Biostatistics Center.

Terminated
Registry status
Phase 3
Development phase
657
Enrollment target

NCT00439374: Clinical Trial Phase 3 study, sponsored by The George Washington University Biostatistics Center.

NCT00439374 is a Phase 3 study that was terminated before completion, run by The George Washington University Biostatistics Center. The registered enrollment target is 657 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00439374, a Phase 3 study, was terminated before completion, sponsored by The George Washington University Biostatistics Center.

TERMINATED
Registry status
Phase 3
Development phase
657 participants
Enrollment target

Study Summary

The purpose of this study is to see if giving progesterone medication to pregnant women, who have never delivered a baby after 19 weeks of pregnancy and who have a short cervix, lowers the risk of early delivery and improves the health of their baby.

Primary Outcome

Number of participants delivering before 37 weeks gestation by indication

Interventions

  • OTHER Placebo Oil
  • DRUG 17 alpha-hydroxyprogesterone caproate

Trial Details

FieldValue
Enrollment Target 657 participants
Start Date 2007-04
Est. Completion 2011-12
Phase Phase 3

Why NCT00439374 stopped before completion

NCT00439374 is an interventional study that assigns participants to a tested intervention. The registered 657 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo Oil is the first listed.

NCT00439374 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00439374 about?

NCT00439374 is a clinical study titled "RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix". The purpose of this study is to see if giving progesterone medication to pregnant women, who have never delivered a baby after 19 weeks of pregnancy and who have a short cervix, lowers the risk of early delivery and improves the health of their baby.

What is the current status of trial NCT00439374?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 657 participants. The study started on 2007-04. Estimated completion is 2011-12.

What interventions are being tested in trial NCT00439374?

The interventions under investigation include: Placebo Oil (OTHER), 17 alpha-hydroxyprogesterone caproate (DRUG).

Who is sponsoring clinical trial NCT00439374?

This trial is sponsored by The George Washington University Biostatistics Center, which has 24 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00439374's enrollment target sits among peer trials

657 564th of 2000 higher than 1,436 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03671044 · 657 participants · Phase 3

    A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

  • NCT05338697 · 657 participants

    Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

  • NCT05407129 · 656 participants · NA

    Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences

  • NCT06127199 · 656 participants · NA

    Contraceptive Efficacy Study of Ovaprene

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00439374, the US trial registry maintained by the National Library of Medicine. NCT00439374 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.